Stock Comparison
HALO vs VRTX
Halozyme Therapeutics Inc and Vertex Pharmaceuticals Inc side by side — valuation, profitability, growth and risk.
Valuation
Market Cap
$12.00B
$123.94B
P/E (TTM)
29.7
28.5
Forward P/E
14.0
25.7
Price/Sales
7.2
9.9
Price/Book
83.6
6.1
EV/EBITDA
19.5
23.2
Dividend Yield
—
—
Profitability
Net Margin
23.13%
35.40%
Operating Margin
56.96%
38.97%
Return on Equity
173.70%
23.50%
Return on Assets
25.50%
11.90%
Growth (YoY)
Revenue Growth
47.70%
12.50%
Earnings Growth
42.90%
8.00%
Price & Risk
Beta
0.8
0.3
52-Week High
$103.12
$529.65
52-Week Low
$61.63
$376.62
Analyst Target
$88.22
$559.28
Compare HALO and VRTX your own way
Try mrmarket.ai freeFigures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.